Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
256-270 of 4213 results
Debiopharm unveils positive phase 2 trial with Debio 1450 in ABSSSI patients
Debiopharm International has unveiled positive results from a large Phase II study of the staphylococcal-selective antibiotic Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Contract Research & Services > Clinical Trials > News
Pfizer’s Humira biosimilar shows positive top line results
By PBR Staff Writer
Results from a Reflections B538-02 study with Pfizer’s investigational Humira (adalimumab) biosimilar, PF-06410293, demonstrated that the drug met its primary endpoint, and showed same efficacy to its reference product.
Contract Research & Services > Clinical Trials > News
Seattle Genetics starts phase 1 trial of SGN-CD352A in relapsed or refractory multiple myeloma
Seattle Genetics has enrolled the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM).
Contract Research & Services > Clinical Trials > News
Ionis’ type 2 diabetes candidate shows positive results in phase 2 study
Ionis Pharmaceuticals has reported positive data from phase 2 study of IONIS-GCGR Rx in patients with type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Sun Pharma’s dry eye drug Seciera demonstrates positive results in phase 3 trial
By PBR Staff Writer
Sun Pharma’s drug Seciera, indicated for the treatment of dry eye disease, has demonstrated positive results in a 12-week multicentre phase-3 clinical trial.
Contract Research & Services > Clinical Trials > News
NewVac’s ovarian cancer combination meets primary endpoints in phase II trial
NewVac has met all primary endpoints in the Phase II Clinical Trial of Quisinostat, novel selective oral histone deacetylase (HDAC1) inhibitor, which the company licensed from Janssen Pharmaceutica.
Contract Research & Services > Clinical Trials > News
Zynerba starts phase 2 trial of ZYN002 in Fragile X syndrome
By PBR Staff Writer
Zynerba Pharmaceuticals has started an exploratory phase 2 clinical trial of ZYN002 cannabidiol (CBD) topical gel in children with Fragile X syndrome, genetic disorder that causes intellectual disability, behavioral and learning challenges.
Contract Research & Services > Clinical Trials > News
Incyte treats first patient in clinical trial program for ruxolitinib in GVHD
By PBR Staff Writer
Incyte has treated first patient in the clinical trial program of ruxolitinib (Jakafi) for the treatment of steroid-refractory acute graft-versus-host disease (GVHD).
Contract Research & Services > Clinical Trials > News
Alexion’s eculizumab fails to meet primary endpoint in phase 2/3 trial
Alexion Pharmaceuticals has reported results from the PROTECT Study, a Phase 2/3 registration trial of eculizumab (Soliris) for the prevention of delayed graft function (DGF) after kidney transplantation in adult recipients of a deceased donor kidney.
Contract Research & Services > Clinical Trials > News
Roche's emicizumab haemophilia drug succeeds in phase III trial
By PBR Staff Writer
A phase 3 clinical trial assessing Roche's emicizumab haemophilia drug in patients 12 years old and older met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Inovio’s Zika vaccine evokes strong immune responses in first human trial
By PBR Staff Writer
Inovio Pharmaceuticals said that its DNA-based Zika vaccine (GLS-5700) induced robust immune responses in an early-stage study in human volunteers who have not been infected with the virus.
Contract Research & Services > Clinical Trials > News
Merrimack halts breast cancer treatment trial
By PBR Staff Writer
Merrimack Pharmaceuticals has stopped a phase 2 trial of its breast cancer treatment after an analysis suggested the drug would unlikely show benefit over the comparator treatments.
Contract Research & Services > Clinical Trials > News
ViiV Healthcare starts HIV prevention study with cabotegravir
By PBR Staff Writer
ViiV Healthcare has commenced a phase III study to assess cabotegravir, a long-acting injectable integrase strand transfer inhibitor, for the prevention of HIV infection.
Contract Research & Services > Clinical Trials > News
GSK commences phase III study for triple combination asthma therapy
By PBR Staff Writer
GlaxoSmithKline (GSK) and Innoviva have started started a triple combination therapy phase III study for the treatment of asthma.
Contract Research & Services > Clinical Trials > News
Akcea Therapeutics' metabolic disorder drug succeeds in phase 3 trial
Ionis Pharmaceuticals’ subsidiary Akcea Therapeutics announced that its phase 3 COMPASS clinical trial for volanesorsen met its primary end point of significant mean reduction in triglycerides in patients with severe hypertriglyceridemia
Contract Research & Services > Clinical Trials > News
256-270 of 4213 results